29 patents
Utility
Gene Therapies for Neurodegenerative Disease
21 Dec 23
The disclosure relates, in some aspects, to compositions and methods for treatment of neurodegenerative disease, for example Alzheimer's disease.
Asa Abeliovich, Sitharthan Kamalakaran, Benjamin Shykind, Edmund c. Schwartz, Anindya Kumar Sen
Filed: 24 Nov 21
Utility
Gene therapies for lysosomal disorders
7 Nov 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 3 Oct 18
Utility
Gene Therapies for Neurodegenerative Disorders
2 Nov 23
The disclosure relates to compositions and methods for treatment of neurodegenerative disorders, such as fronto-temporal dementia (FTD).
Asa ABELIOVICH, Jeffrey SEVIGNY, Travis LEWIS, Olga USPENSKAYA
Filed: 10 Aug 21
Utility
Gene therapies for lysosomal disorders
31 Oct 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 3 Oct 18
Utility
Gene Therapies for Lysosomal Disorders
5 Oct 23
The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as Parkinson's disease and Gaucher disease.
Asa ABELIOVICH, Jeffrey SEVIGNY, Travis LEWIS, Olga USPENSKAYA
Filed: 10 Aug 21
Utility
Aav Vectors Encoding Parkin and Uses Thereof
28 Sep 23
The disclosure relates, in some aspects, to compositions and methods for delivery of transgenes to a subject.
Asa Abeliovich, Benjamin Shykind
Filed: 3 Aug 21
Utility
Gene Therapies for Lysosomal Disorders
14 Sep 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease.
Asa ABELIOVICH, Laura HECKMAN, Herve RHINN
Filed: 11 Apr 23
Utility
Gene therapies for lysosomal disorders
30 May 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 6 Apr 20
Utility
Gene therapies for lysosomal disorders
23 May 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 18 Jun 20
Utility
Gene therapies for lysosomal disorders
28 Mar 23
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 6 Apr 20
Utility
Recombinant Adeno-associated Virus Compositions and Methods for Producing Same
21 Apr 22
Disclosed herein are compositions comprising recombinant adeno-associated virus (rAAV), as well as recombinant baculovirus systems and methods of using the same for producing and purifying such compositions.
YONG DAI, Jingmin ZHOU, Garrett DANIELS, Jonathan CHAN, Jorge HALLER, Stuart NELSON
Filed: 15 Oct 21
Utility
Gene Therapies for Neurodegenerative Disease
13 Jan 22
The disclosure relates, in some aspects, to compositions and methods for treatment of neurodegenerative disease, for example Alzheimer's disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 26 Nov 19
Utility
Gene Therapies for Lysosomal Disorders
28 Oct 21
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa ABELIOVICH, Laura HECKMAN, Herve RHINN
Filed: 7 Jul 21
Utility
Gene Therapies for Neurodegenerative Diseases
26 Aug 21
The disclosure relates, in some aspects, to compositions and methods for treatment of neurodegenerative diseases (e.g., amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), Alzheimer's disease, Gaucher disease, Parkinson's disease, Lewy body dementia, or a lysosomal storage disease).
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 23 Oct 18
Utility
Gene therapies for lysosomal disorders
13 Jul 21
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 17 Sep 20
Utility
Gene Therapies for Lysosomal Disorders
14 Jan 21
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa ABELIOVICH, Laura HECKMAN, Herve RHINN
Filed: 17 Sep 20
Utility
Gene therapies for lysosomal disorders
16 Nov 20
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 19 Nov 19
Utility
Gene Therapies for Lysosomal Disorders
28 Oct 20
The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn, Franz HEFTI
Filed: 9 Apr 20
Utility
Gene Therapies for Lysosomal Disorders
21 Oct 20
The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD).
Asa ABELIOVICH, Laura HECKMAN, Herve RHINN, Li Chin WONG, Hsuan-Ni LIN, Franz HEFTI
Filed: 9 Apr 20
Utility
Gene Therapies for Lysosomal Disorders
7 Oct 20
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease.
Asa Abeliovich, Laura Heckman, Herve Rhinn
Filed: 1 Apr 20